Precise Transplantation of hAESCs Into the Ventricle for Parkinson's Disease.

T

Tongji University

Status and phase

Not yet enrolling
Early Phase 1

Conditions

Parkinson's Disease

Treatments

Biological: placebo (saline)
Biological: hAESCs treatment

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT05435755
2020YFA0112600

Details and patient eligibility

About

The purpose of this study is to evaluate the safety of multiple treatments of hAESCs treatments, while exploring the effectiveness of hAESCs treatments for PD.

Full description

The study plans to use randomized controlled trial and recruit 12 participants with Idiopathic Parkinson's disease. The trial will be divided into two groups, hAESCs treatment group and control group, each group 6 subjects. Through surgical robot technology, hAESCs will be precisely multiple transplanted into the lateral ventricles, that is two times consolidation hAESCs treatments or placebo were added to the four times basic hAESCs treatments. Therapeutic safety and effectiveness of multiple treatments of hAESCs on PD will be evaluated to further develop the optimal stem cell treatment strategy.

Enrollment

12 estimated patients

Sex

All

Ages

30 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • 30-70 years old, with more than 5 years primary Parkinson's disease history, male or female;
  • The "off-age" UPDRS exercise score is between 38 and 70 points, two times before the operation, the "down period" UPDRS exercise score was stable, that is, (high value - low value) / high value ≤ 10%;
  • The Parkinson treatment is stable for more than 3 months;
  • Levodopa treatment was effective;
  • No general anesthesia contraindications, no contraindications to stereotactic surgery and other conditions that interfere with clinical evaluation;
  • No abnormalities affecting cell transplantation were found through the cranial MRI;
  • Patients shall be properly cared during treatment, and caregivers can provide transplantation situations and assistance to the researcher if necessary.

Exclusion criteria

  • Atypical Parkinson's disease, such as Parkinson's syndrome, secondary Parkinson's disease;
  • Only having tremor syndrome;
  • "off period" or "on period" has serious movement disorders and cannot complete any routine exercise tasks;
  • Symptoms of severe neurological deficits caused by other diseases;
  • Severe mental symptoms or dementia;
  • Patients are unwilling to cooperate or incapable of completing self-evaluation, and cannot complete the evaluator with the help of a doctor;
  • History of striatum or extrapyramidal surgery, including deep brain stimulation (DBS);
  • Injecting apomorphine treatment;
  • Abnormal blood coagulation or ongoing anticoagulation therapy;
  • Women of childbearing age who do not take effective contraception;
  • Pregnant or lactation;
  • Patients who have participated in other clinical studies of drugs or medical devices within 3 months;
  • Botox toxin, phenol, subarachnoid injection of baclofen or interventional therapy for the treatment of dystonia or spasticity within 6 months;
  • History of seizures or prophylactic anti-epileptic drugs;
  • Alcohol or drug abuse;
  • Severe cognitive impairment, depression, or behavioral disorder, defined as the Mini-Mental State Assessment Scale (MMSE) of less than 26 points, and the Hamilton Depression Rating Scale (HAMD) of greater than 35 points;
  • Malignant tumor or active infection within 5 years;
  • Serum virology showed positive results for hepatitis C virus (HCV) , treponema pallidum (TP) or HIV; Active hepatitis B (hepatitis B surface antigen (HBsAg) and/or hepatitis B core antibody (HBcAb) positive, and peripheral blood HBV DNA titer ≥1×10^3 IU/ mL);
  • Abnormal liver and kidney function tests in the laboratory, liver and kidney function is defined as Alanine aminotransferase(ALT), Aspartate aminotransferase(AST) is less than 2.5 times the upper limit of normal, blood urea nitrogen (BUN) and Creatinine(Cr) are less than the upper limit of normal.
  • Other conditions considered ineligible for inclusion by the investigator.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

12 participants in 2 patient groups, including a placebo group

hAESCs treatment
Experimental group
Description:
A total of 6 times hAESCs transplants will be performed. 50 million (in 2ml) hAESCs will be transplanted into the ventricle of participants through the Ommaya sac (set as day 0 at the beginning of the trial). Subsequently, hAESCs ventricle transplants will be performed at 1 month ±5 days, 2 months ±5 days, 3 months ±5 days, 6 months ±5 days, and 9 months ±5 days after the first cell transplantation, with a volume of 50 million cells (in 2 ml) each time.
Treatment:
Biological: hAESCs treatment
Control group
Placebo Comparator group
Description:
Four times hAESCs transplants and two times placebo (cell preservation solution) injections will be performed by Ommaya sac. 50 million (in 2ml) hAESCs will be transplanted into the ventricle of participants (set as day 0 at the beginning of the trial). Subsequently, hAESCs will be transplanted into the ventricle for 3 times, respectively, at 1 month ±5 days , 2 months±5 days , and 3 months ±5 days after the first cell transplantation, with a volume of 50 million cells (in 2 ml) each time. Ventricle injection of 2 ml placebo (cell preservation solution) will be performed at 6 months ±5 days and 9 months ±5 days after the first cell transplantation.
Treatment:
Biological: placebo (saline)

Trial contacts and locations

1

Loading...

Central trial contact

Jingwen Wu, Dr

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems